Lundbeck breathes life into stranded molecule to treat new diseases
![Photo: Lundbeck / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13168174.ece/ALTERNATES/schema-16_9/doc7gvlmsxcls9133mrke0a.jpg)
Lundbeck means business in picking drug candidate LU AG06466 back up again. The Danish pharmaceutical company is testing the drug in three phase I trials. In March 2020, it failed as a treatment for Tourette's syndrome in a phase II trial.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Lundbeck: acquisitions must be well considered
For subscribers
Lundbeck closes RNA deal worth USD 109m with US biotech firm
For subscribers
Takeda surpasses analyst forecasts in Q1
For subscribers